T raumatic space occupying lesions and cerebral edema may result in a reduction of the intracranial volume reserve followed by a rise in intracranial pressure (ICP). Subsequently, elevated ICP may lead to herniation of brain tissue, inadequate cerebral perfusion, ischemia, and death (1, 2) . Monitoring and treatment of raised ICP are therefore considered key elements of clinical management of severe traumatic brain injury (TBI) (3) .
ICP monitoring allows early detection of pressure changes and can guide treatment of elevated ICP (4, 5) . Based on observational and case studies (6) (7) (8) , international guidelines recommend routine ICP monitoring in severe TBI (9) (10) (11) . However, the efficacy of ICP monitoring has never been verified in randomized controlled trials and recent studies have questioned the benefits of ICP monitoring. In one retrospective cohort study, a center using ICP monitoring was compared to a center not using ICP monitoring. Patients in the ICP monitoring center received longer mechanical ventilation and more intense therapy but did not have better outcome (12) . Other reports concluded that routine ICP monitoring is associated with worse outcome (13) and higher risk of extracranial complications (14) . These counterintuitive findings generated many responses from the field (15) (16) (17) (18) (19) (20) (21) (22) , pointing out that there is confounding by indication. Patients undergoing ICP monitoring probably sustained more severe injuries than those not undergoing ICP monitoring, and therefore have a worse outcome. These comments underscore that in studies evaluating the effect of guidelines on outcome, identification of and controlling for confounding factors are important.
Objective: To determine adherence to Brain Trauma Foundation guidelines for intracranial pressure monitoring after severe traumatic brain injury, to investigate if characteristics of patients treated according to guidelines (ICP+) differ from those who were not (ICP-), and whether guideline compliance is related to 6-month outcome.
Design: Observational multicenter study.
Patients: Consecutive severe traumatic brain injury patients (16 yrs, n = 265) meeting criteria for intracranial pressure monitoring.
Measurements and Main Results: Data on demographics, injury severity, computed tomography findings, and patient management were registered. The Glasgow Outcome Scale extended was dichotomized into death (Glasgow Outcome Scale extended = 1) and unfavorable outcome (Glasgow Outcome Scale extended 1-4). Guideline compliance was 46%. Differences between the monitored and nonmonitored patients included a younger age (median 44 vs. 53 yrs), more abnormal pupillary reactions (52% vs. 32%), and more intracranial pathology (subarachnoid hemorrhage 62% vs. 44%; intraparenchymal lesions 65% vs. 46%) in the ICP+ group. Patients with a total intracranial lesion volume of ~150 mL and a midline shift of ~12 mm were most likely to receive an intracranial pressure monitor and probabilities decreased with smaller and larger lesions and shifts. Furthermore, compliance was low in patients with no (Traumatic Coma Databank score I −10%) visible intracranial pathology. Differences in case-mix resulted in higher a priori probabilities of dying (median 0.51 vs. 0.35, p < .001) and unfavorable outcome (median 0.79 vs. 0.63, p < .001) in the ICP+ group. After correction for baseline and clinical characteristics with a propensity score, intracranial pressure monitoring guideline compliance was not associated with mortality (odds ratio 0.93, 95% confidence interval 0.47-1.85, p = .83) nor with unfavorable outcome (odds ratio 1.81, 95% confidence interval 0.88-3.73, p = .11).
Conclusions: Guideline noncompliance was most prominent in patients with minor or very large computed tomography abnormalities. Intracranial pressure monitoring was not associated with 6-month outcome, but multiple baseline differences between monitored and nonmonitored patients underline the complex nature of examining the effect of intracranial pressure monitoring in observational studies. (Crit Care Med 2012; 40: 1914 -1922 Key WOrDS: computed tomography; Glasgow Outcome Scale; guideline adherence; intracranial pressure; multivariate analysis; traumatic brain injury factors influencing intracranial pressure monitoring guideline compliance and outcome after severe traumatic brain injury* The Brain Trauma Foundation (BTF) guidelines are thoroughly constructed and widely accepted guidelines for the management of TBI. The BTF advises ICP monitoring in all salvageable severe TBI patients with a computed tomography (CT) scan revealing intracranial pathology (level II recommendation) or in severe TBI patients with a normal CT scan but with two or more of the following risk factors: age over 40 yrs, unilateral or bilateral motor posturing, or systolic blood pressure <90 mm Hg (level III recommendation) (9) . It has been suggested that implementation and strict adherence to the international guidelines results in a reduction of mortality (6, 7, 23, 24) . However, considerable variation in the appliance of ICP monitors has been reported across studies (3, 6, (25) (26) (27) .
As part of a multicenter study we determined compliance to the BTF guidelines for ICP monitoring. Our primary goal was to identify demographic and injury characteristics associated with guideline compliance. We hypothesized that a low a priori probability as well as a high a priori probability for death or unfavorable outcome would decrease the likelihood of guideline compliance.
Second, we assessed in a multivariate model, correcting for potential confounders by using a propensity score, whether ICP monitoring guideline compliance is a predictor for long-term outcome after severe TBI.
MATERIALS AND METHODS
Design and Setting. The Prospective Observational COhort Neurotrauma project is a study of epidemiology, acute care, and outcome in the first year after moderate and severe TBI. Five of 11 specialized (level I) trauma centers in The Netherlands participated. These centers all use standardized hospital developed protocols for treatment of severe TBI patients, which are based on international guidelines set up by the BTF (www.braintrauma.org). See reference (28) for detailed information about the study.
Patient Selection. In Prospective Observational COhort Neurotrauma, all patients with TBI admitted to the emergency department (ED) with a Glasgow Coma Scale (GCS) score ≤13 between June 1, 2008 and May 31, 2009 were registered in a database. When intubated at the scene of injury, the GCS score obtained before intubation (≤13) was used as the qualifier to determine eligibility for study inclusion. Exclusion criteria were age <16 yrs, and hospital admission >72 hrs after the injury was sustained. For this study, we selected those patients meeting BTF criteria for ICP monitoring (9) . Two selection criteria were defined: 1) patients with severe TBI (GCS ≤8 on ED admission) and an abnormal CT scan (revealing hematomas, contusions, swelling, herniation, or compressed basal cisterns); 2) patients with severe TBI without CT abnormalities but with at least two of the following criteria: age >40 yrs, unilateral or bilateral motor posturing (ED GCS motor score ≤3), or an episode of systolic blood pressure <90 mm Hg before hospital arrival or at the ED.
Patients in whom a first CT scan was unavailable or who were not admitted to one of the participating hospitals (i.e., transferred from the ED to a nonparticipating hospital, discharged home, or who died at the ED or operating room) were excluded, as monitoring indication or guideline compliance could not be determined. In addition, patients with a gunshot injury were excluded.
Data Collection and Definitions. Data were collected from medical records and entered into a database by trained research staff. Collected variables included age, gender, injury mechanism, GCS scores, pupillary reactions, hypotensive episode (yes = systolic blood pressure <90 mm Hg, suspected = on clinical grounds), hypoxic episode (at injury scene or ED, yes = SaO 2 <90% or PaO 2 <8 kPa, suspected = on clinical grounds), glucose (mmol/L) and hemoglobin (g/dL) levels. Severity scores included the Injury Severity Score and Abbreviated Injury Scores. Major extracranial trauma was defined as Abbreviated Injury Score ≥3 in one or more body regions other than the head.
We registered the length of hospital and intensive care unit (ICU) stay, sedation and mechanical ventilation at the ICU, intra-and extracranial surgery. Craniotomy was defined as "acute" if scheduled after assessment of the initial head CT scan. Brain-specific treatment included osmotherapy (mannitol or hypertonic saline), vasopressor medication to maintain cerebral perfusion pressure (not registered if a patient received vasopressive agent for systemic blood pressure support), hyperventilation ([yes = PaCO 2 ≤4 kPa] and only registered when documented as treatment strategy in medical records), cerebrospinal fluid drainage, hypothermia (body temperature <35°C), and use of barbiturates. Increased ICP was defined as any period with a measured ICP >20 mm Hg.
The first acquired CT scan was evaluated. If not available, the second scan was assessed provided that it was made within 6 hrs after the initial scan and prior to any neurosurgical intervention. Scans were scored using a standardized data sheet (29) (30) (31) . The Traumatic Coma Databank (TCDB) score (32) and the presence and volume of subdural hematoma, epidural hematoma and intraparenchymal lesions were recorded. Lesion figure 1. Flow chart study inclusion. BTF, Brain Trauma Foundation; CT, computed tomography; CTabn+, CT scan which reveals hematomas, contusions, swelling, herniation, or compressed basal cisterns; CTabn-, CT scan which does not reveal hematomas, contusions, swelling, herniation, or compressed basal cisterns; ED, emergency department; GCS, Glasgow Coma Scale; GOSE, Glasgow Outcome Scale Extended; ICP, intracranial pressure; ICP+, patients who received an ICP monitor; ICP-, patients who did not receive an ICP monitor; ICU, intensive care unit; OR, operating room; POCON, Prospective Observational COhort Neurotrauma.
volume was calculated using the ellipsoid method (33, 34) . Furthermore, we recorded the presence of microbleeds (maximum diameter of 5 mm), subarachnoid hemorrhage, and midline shift and the status of the ambient cisterns and fourth ventricle.
Six-month outcome was assessed with the Glasgow Outcome Scale Extended (GOSE), an eight-point scale ranging from 1 (dead) to 8 (good recovery). The GOSE was determined through a postal questionnaire or a structured telephone interview (35, 36) .
Protocol Approval and Patient Consent. The study protocol was approved by the local ethics committee of the coordinating hospital (Radboud University Nijmegen Medical Center). The other participating hospitals all provided a feasibility statement. For follow-up by telephone interview, verbal informed consent was obtained, and for outcome assessment through postal questionnaires, we gained written informed consent.
Statistical Analysis. All statistical analyses were performed using SPSS version 16.0. (SPSS, Inc., Chicago, IL). Unless stated otherwise, a p value <.05 was considered statistically significant. Patients were grouped as guideline compliant (ICP+) or noncompliant (ICP-).
Characteristics of the ICP+ and ICP-groups were compared using a Mann-Whitney U test in case of ordinal variables or when assumptions of normality were violated, and Pearson's chisquare tests were used for nominal variables. As a nonlinear relationship was expected, the association between intracranial lesion volume and midline shift with ICP monitor placement was examined in univariate analyses with restricted cubic spline functions (37) .
The propensity score corresponds to the probability of a patient receiving an ICP monitor given a range of baseline demographic and clinical variables (38) . To calculate the patient's propensity score, a multivariate logistic regression model was performed with ICP monitoring (yes/no) as outcome variable and all baseline demographic and injury characteristics with p < .10 (in univariate analyses) as explaining variables. Missing values were included as a separate "unknown" category. The proportion explained variance (Nagelkerke R 2 ) and predictive accuracy (area under the receiver operating characteristic curve) were assessed.
To investigate whether ICP monitoring guideline compliance is a predictor for patient outcome, we performed two multivariate logistic regression analyses with 6-month outcome dichotomized as dead (yes/no) and unfavorable (yes = GOSE 1-4 /no = GOSE 5-8). Guideline compliance was entered into the model as independent variable together with the patient's propensity score to adjust for potential confounding by indication.
Finally, the International Mission for Prognosis and Analysis of Clinical Trials in TBI prediction rule was used to calculate the probability of death (P death6 ) and unfavorable outcome (P unfav6 ) at 6 months after injury. Where possible, the full laboratory model was used. In case of insufficient data, probability of death was calculated using either the extended or the core model (39) .
RESULTS

Patient Demographics and Early
Injury Characteristics. A total of 265 patients met BTF criteria for ICP monitoring and were included (Fig. 1 ). Patients were predominantly male (68%) and involved in road traffic accidents (50%) ( Table 1 ). An ICP monitor was inserted in 123 (46%) patients and guideline compliance ranged between 21% and 64% across centers. Comparison of demographic and injury characteristics between the ICP+ and ICP-groups revealed multiple differences. The ICP+ group was younger (median 44 vs. 53 yrs, p < .001), had lower GCS scores (GCS at ED 3 vs. 3 [3] [4] [5] [6] , p < .01), more abnormal pupillary reactions (52% vs. 32%, p < .01), and more major extracranial injuries (57% vs. 39%, p < .01) than the ICP-group.
Evaluation of the CT scan was based on 252 (95%) first and on 9 (3.4%) second acquired scans. In four cases (1.5%), a CT scan was unavailable but patients were included in this study because they had undergone acute craniotomy. Intracranial abnormalities were detected in 245 (93%) patients of whom 121 (49%) received an ICP monitor. Twenty (7.5%) patients met BTF criteria but had a normal first CT scan (TCDB I). Two (10%) of these patients received an ICP monitor. Comparison of intracranial pathology between ICP+ and ICP-groups (Table  2) revealed that almost all injury types were more common in the ICP+ group, including the presence of subarachnoid hemorrhage (62% vs. 44%, p < .01), subdural hematoma (59% vs. 40%, p < .01), and intraparenchymal lesions (65% vs. 46%, p < .01). The ICP+ group revealed larger total lesion volumes compared to the ICP-group (median 22.7 mL vs. 4.1 mL, p < .01). Figure 2 shows the probability of ICP monitoring in relation to total intracranial lesion volume and midline shift, examined with a restricted cubic spline model. Note that for lesion volume, outliers (1.5%) were truncated to the upper limit of 355 mL. Both figures reveal an n-shaped curve with the highest probabilities of ICP monitor placement in lesion volumes at approximately 150 mL and a midline shift at around 12 mm. Patients with smaller but also with larger lesion volumes or midline shifts were less likely to receive ICP monitoring.
Predicting ICP Monitoring Compliance. Baseline demographics and injury characteristics that differed (at p < .10) between the ICP+ and ICP-groups were entered into a multivariable model to predict ICP monitor placement. The corresponding odds ratios (ORs), 95% confidence intervals (CIs), and p values are reported in Tables 1 and 2 . The following variables were significant predictors of guideline compliance: age, GCS at injury scene and ED, pupillary reactions, status of the ambient cisterns and the fourth ventricle, and total lesion volume. The model explained 52% of the variance in ICP monitor placement (Nagelkerke R 2 ) and had an area under the curve of 0.86 (95% CI 0.81-0.90).
Patient Management. The median duration of ICP monitoring was 4.6 days, and a raised ICP was measured in 71% (Table  3) . Patients with ICP monitoring had a significantly longer ICU (median 10.8 vs. 2.7 days, p < .001) and hospital (median 22.0 vs. 7.5 days, p < .001) stay compared to patients without ICP monitoring. Except for 13 (9.2%) patients in the ICP-group, all were mechanically ventilated and duration of ventilation was longer in the ICP+ group (median 7.7 days vs. 1.3 days, p < .001). All brain-specific therapies, except delayed craniotomy, were more common in the ICP+ group. In two patients without ICP monitoring, cerebrospinal fluid drainage was started because of a developing hydrocephalus. Predicted and Actual 6-Month Outcome. Table 4 shows the actual 6-month outcome and the probabilities for death and unfavorable outcome for the ICP+ and ICP-groups. The follow-up rate for 6 month survival was 94%, and in 89% a GOSE score could be obtained (Fig. 1) . No difference in observed 6-month mortality was found between the ICP+ and ICP-groups, but the ICP+ group did show a higher rate of unfavorable outcome (74% vs. 53%, p = .01) and unfavorable survival (44% vs. 20%, p < .01).
To calculate P death6 and P unfav6 , the full IMPACT model was used in 219 (83%), the extended model in 10 (4.0%), and the core model in 18 (6.8%) patients. In 18 (6.8%) patients, probabilities could not be calculated due to missing data. Monitored patients showed a higher a priori probability of death (median 0.51 vs. 0.35, p < .001) and unfavorable outcome (median 0.79 vs. 0.63, p < .001). Guideline compliance was highest in patients with an intermediate probability of death (61% compliance in P death6 .4-.6), whereas compliance was lowest in patients with low probability of dying (21% compliance in P death6 0-.2) (bottom row in Fig. 3A) . When probability for unfavorable outcome was considered (bottom row in Fig. 3B ), guideline compliance was highest in patients with a P unfav6 between .6 and .8 (56%) and declined with lower probability of unfavorable outcome.
Relationship 1-2 vs. 3-8 and GOSE 1-3 vs. 4-8) were used to dichotomize outcome into unfavorable and favorable. In neither of these post hoc analysis, ICP monitoring was associated with outcome (p > .50).
To explore whether ICP monitoring was related to outcome in specific subgroups, we stratified patients by predicted outcome probability. Within each predicted outcome category, we compared actual outcome between the ICP+ and ICP-group. (Fig. 3A and 3B ) No significant differences in survival were detected in any of the subgroups. However, patients with a predicted unfavorable outcome probability between .6 and .8 who received an ICP monitor had a significantly higher rate of observed unfavorable outcome (78%) than patients who did not receive an ICP monitor (54%, p = .04). Nevertheless, after correction for case-mix by using the propensity score this effect became nonsignificant, (OR 2.39 [95% CI 0.53-10.8]).
DISCUSSION
In this prospective observational multicenter study, adherence to BTF guidelines for ICP monitoring was <50%. Compared to patients who were not monitored, the ICP monitored group was younger and had lower GCS scores, more abnormal pupillary reactions, more severe systemic injuries, and more lesions on the initial CT scan. This variability in baseline characteristics between the ICP-compliant and noncompliant groups resulted in a different a priori different probability of dying and unfavorable outcome as calculated with the IMPACT prediction model. The proportion of patients receiving an ICP monitor was highest in patients with a 40%-60% chance of death while guideline compliance sharply declined in patients with a low probability of dying. In addition, guideline compliance was highest in patients with intermediate total lesion volumes and midline shifts and decreased in patients with smaller but also with very large lesions or shifts. These findings corroborate with a previous study (40) illustrating that both the "best" and "worst" patients are least likely to undergo ICP monitoring. Furthermore, our results underline the need for adequate correction of confounding variables when assessing the effect of interventions in observational cohort studies.
In crude analyses, guideline compliance was associated with poorer outcome, most notably in patients with a 60%-80% chance of unfavorable outcome. However, after adjustment for variability in baseline characteristics by including a propensity score in a logistic regression model, no relationship was found between ICP monitoring and 6-month outcome. Our findings are in agreement with studies reporting no effect of ICP monitoring on outcome (12, 14, 40) but contrast with two studies reporting ICP monitoring to be associated with either increased (8) or decreased survival (13) . Although all previous studies applied multivariate correction methods, only few CT characteristics were assessed (i.e., the TCDB or Abbreviated Injury Score head score). Individual CT characteristics such as lesion type, lesion volume, midline shift, the status of the ambient cisterns and the fourth ventricle are predictors of outcome (29, 31, 41) . As this study demonstrates, detailed knowledge on intracranial pathology probably plays an important role in clinical decision making. Many individual signs of severe injury on CT were more prominent in the guideline compliant than in the noncompliant group and had high ORs for ICP monitoring. Not incorporating specific information on CT findings, like volume or shift, may explain the contrasting findings in previous studies. We advocate that individual CT characteristics deserve more attention as confounding factors in analyses of the effect of ICP monitoring.
The overall guideline compliance rate in our study (46%) is in line with compliance rates (43%-67%) reported elsewhere (12, 13, 25, 40, 42, 43) . Compliance ranged between 21% and 64% across centers, reflecting variability in approach and treatment of TBI patients. However, also other between-center differences in baseline characteristics, like age, GCS, and CT characteristics (data not shown in this study), may explain variation in ICP monitoring rates.
Interestingly, compliance was almost five times lower in patients with a normal CT scan and two or more risk factors (10%) compared to patients with visible intracranial pathology (49%). The BTF recommendation for ICP monitoring in patients without visible intracranial pathology stems from a prospective study executed in the 1970's reporting raised ICP in eight (15%) of 61 severe TBI patients with a normal CT (44) . In our study, the two patients without initial intracranial pathology who received an ICP monitor both experienced a period of raised ICP. Our study was not designed to assess the risk of increased ICP in patients with a normal CT scan but confirms that severe TBI patients without initial intracranial pathology may develop raised ICP. Also in patients with a TCDB II classification, compliance was relatively low (33%). Yet, in a recent series of ICP-monitored patients, 50% with a TCDB II classification developed raised ICP (45) . The noncompliance in patients without or with minor visible pathology suggests that clinicians are often not convinced that ICP monitoring in this subgroup of severe TBI patients is necessary; therefore, the extent of CT abnormalities that require ICP monitoring deserves further investigation.
When assessing the effect of ICP monitoring on patient outcome, it is not the insertion of an ICP device in itself but the subsequent treatment of raised ICP (or decreased cerebral perfusion pressure) that is thought to mediate outcome. Patients who received an ICP monitor had longer ICU and hospital stays and received up to nine times more (in case of osmotherapy) ICP-and/or cerebral perfusion pressuredirected therapy. More treatment in the guideline compliant group may be a direct result of more intensive monitoring but may also be related to variability in injury severity. It has been suggested that interventions to reduce ICP may sometimes be harmful or inappropriately applied, possibly explaining the absence of an association between ICP monitoring and patient outcome (13) . As we did not examine treatment in terms of dosage, promptness, and length of a certain intervention, we were unable to assess the figure 3. Actual 6-month outcome stratified by predicted 6-month outcome for death (A) and unfavorable outcome (B). ICP, intracranial pressure; ICP+, ICP monitor guideline compliant group; ICP-, ICP monitor guideline noncompliant group. Probability of death and unfavorable outcome was calculated using the International Mission for Prognosis and Analysis of Clinical Trials in TBI model. n, number of patients with and without ICP monitor in each probability group. adequacy of patient management following ICP monitoring in detail.
Our multivariate model including demographic, injury severity, and CT characteristics explained 52% of the variance in ICP monitor placement, suggesting that other factors are involved in the clinical decision-making process. For instance the patient's premorbid level of functioning but also personal expectations of the treating physician may play a role: A Canadian survey among neurosurgeons reported that only 20% had a high level of confidence that ICP monitoring improves outcome (42) . Given that patient management is influenced by many (measurable and nonmeasurable) factors, full correction for potential confounders in an observational cohort study is very difficult and requires large patient numbers. Instead, a randomized controlled trial would be the study design of choice to prove an effect of ICP monitoring on outcome. However, it is unlikely such a trial will be performed as many think it is unethical to withhold ICP monitoring after TBI (46) . Some study limitations need to be addressed. Early clinical parameters such as pupillary reactions and complications at the ED were unknown in <10% of the patients. Six-month GOSE scores were missing in 11% but are in line with follow-up rates reported in other prospective observational studies (29, 47, 48) . We defined severe TBI based on the ED admission GCS score, which may have been influenced by prehospital interventions such as endotracheal intubation and use of sedatives. Furthermore, deterioration of the GCS may occur at a later stage and patients may at that point fulfill the criteria for ICP monitoring. These secondary complications were not included in our analyses. Similarly, we only assessed the initial CT scan but intracranial abnormalities may evolve over time (49) (50) (51) and may later on influence the course of patient management. Some studies have suggested that ICP monitoring is associated with increased chance of developing complications such as infections and hemorrhage (52) (53) (54) , but these variables were not registered in our study. Finally, as we did not collect data on the frequency of neurological examinations or the number of CTs made during ICU admission, we were unable to assess the adequacy of alternative monitoring methods across the two groups.
In conclusion, this multicenter cohort study showed multiple baseline differences between severe TBI patients with and without ICP monitoring in age, injury severity, and intracranial pathology. These differences in case-mix resulted in higher a priori probabilities of death and unfavorable outcome in patients with ICP monitoring and emphasize the complexity of studying the effect of ICP monitoring in an observational study. After adjustment for baseline characteristics, our study showed no significant relationship between ICP monitoring and death, or unfavorable outcome. However, conclusions about the (absence of an) effect of ICP monitoring should be drawn with caution as correction for all potential confounders is difficult. ICP, intracranial pressure; ICP+, ICP monitor guideline compliance group; ICP-, ICP monitor guideline noncompliance group; GOSE, Glasgow Outcome Scale Extended; P death6 , IMPACT calculated probability of mortality 6 months after injury; P Unfav6 , IMPACT calculated probability of unfavorable outcome 6 months after injury.
a Chi-square test; b Mann-Whitney U test. Values are reported as n (%) or median (interquartile range).
